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Abstract
Background: Neutral lipid storage disease with myopathy (NLSDM) is a rare lipid
metabolism disorder. In this study, we evaluated some circulating miRNAs levels in
serum samples and the MRI of three affected siblings.
Methods: Three members of one NLSDM family were identified: two brothers and
one sister. Muscles of lower and right upper extremities were studied by MRI.
Expression profile of miRNAs, obtained from serum samples, was detected using
qRT-PCR.
Results: Two brothers presented with progressive skeletal myopathy, while the sister
had severe hepatosteatosis and diabetes. NLSDM patients showed a significant
increase of muscle-specific miRNAs expression compared with healthy subjects. We
found a correlation between hepatic damage and elevation of miRNAs expression
profile of liver origin.
Conclusions: The dysregulation of miRNAs might represent an indicator of skeletal
and hepatic damage and it might be useful to monitor the progression of NLSDM.
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1 | INTRODUCTION
Neutral lipid storage disease with myopathy (NLSDM) is a rare meta-
bolic disorder, associated with mutations of the patatin like phospholi-
pase domain containing 2 (PNPLA2) gene. PNPLA2 encodes adipose
triglyceride lipase, responsible for catalyzing triacylglycerol (TAG)
breakdown.1
To date, only 56 patients have been described, mostly from
Mediterranean countries; cases from Japan, China, and the United
States have also been reported.2,3 There is great variability in phe-
notype, but muscle weakness is usually the first symptom, resulting
in both proximal and distal involvement.3-5 Muscle biopsy reveals
massive lipid storage, muscle atrophy, and rarely fiber necrosis.
Heart and liver injury have been observed in nearly 40% and 20%
of patients, respectively.2,6,7 It is difficult to correlate the severity
of clinical symptoms with PNPLA2 mutations. Most gene variations
lead to total loss or a severe decrease of lipase activity,3-5 but in
some patients these mutations are associated with late and/or mild
progressive myopathy.3,5 NLSDM pathophysiology is still largely
unclear.
Abbreviations: CT, computed tomography scan; myomiRs, muscle-specific miRNA,
microRNA; NLSDM, neutral lipid storage disease with myopathy; PNPLA2, phospholipase
domain containing 2 gene; qRT-PCR, real-time polymerase chain reaction; SIRT1, Sirtuin 1;
TAG, triacylglycerol.
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miRNAs are endogenous, small, single-strand, noncoding RNAs that
act as critical regulators of gene expression at a posttranscriptional level.8
Some miRNAs are tissue-specific, while others are expressed in multiple
tissues. There is evidence that miRNAs are also present in plasma and
serum, and, for this reason, are called circulating miRNAs. The function
and origin of circulating miRNAs are not yet well known.8,9 In particular,
TABLE 1 Clinical and biochemical findings of neutral lipid storage disease with myopathy patients
Patient 1 Patient 2 Patient 3
Age 61 years 58 years 50 years
Sex M F M
Age of NLSDM onset 38 years 50 years 35 years
Neutral lipid accumulation Granulocytes severe severe severe
Muscle severe ND severe
Myopathy Muscle weakness severe Mild weakness only in
right triceps brachii muscle
Progressive in right upper
extremity
Muscle atrophy severe No asymmetric distal atrophy
CK (normal range: 0–180 IU/L) 804–1118 1098 1389
Cardiomyopathy No No No
Liver Hepatosteatosis Mild hepatic steatosis severe No
Hepatic enzymes
(normal range: AST 4–40







Diabetes No Yes No
Plasma triglycerides (normal range: 40–175 mg/dL) 139 125 233
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CK, creatine kinase.
F IGURE 1 Muscle imaging and biopsy of patients 1 and 3. A, CT scan of patient 1 showed severe adipose tissue substitution in posterior
thigh muscles, such as in semimembranosus and semitendinosus (arrow). B, Muscles of the posterior legs, mainly soleus and gastrocnemius, are
completely substituted with fatty infiltration (arrow). MRIs of patient 3 revealed relative preservation of deltoid muscle (asterisk, C) and a slight
fibro-fatty replacement of posterior thigh muscle such as adductor magnus and semimembranosus (arrow, D). E, In the posterior leg, fatty
infiltration is more marked than in the anterior leg and only tibialis posterior and soleus muscles are spared (asterisk). Muscle biopsies showed
vacuoles filled with abnormal lipid droplets (arrows) detected by hematoxylin and eosin stain in patient 1 (F) and patient 3 (H), and Oil-Red-O
stain in patient 1 (G) and patient 3 (I) (scale bar = 100 μm). Abnormal lipid droplet accumulation is mostly observed in type I fibers [Color figure
can be viewed at wileyonlinelibrary.com]
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muscle-specific miRNAs (myomiRs) may be secreted by skeletal muscle
fibers into the systemic circulation actively or passively.9
Alterations of circulating miRNAs have been documented in several
muscular dystrophies and other clinical conditions, such as obesity and
insulin resistance. Therefore, they could be used as biomarkers of pro-
gression in neuromuscular and metabolic disorders.10-13
The myomiRs act as muscle regeneration and differentiation regu-
lators and their balance aids in maintaining muscle homeostasis under
normal cellular conditions.14 MiR-206 plays a crucial role in muscle
regeneration and maturation15 and is widely expressed in newly-
formed muscle fibers. It is also implicated in the modulation of muscle
mass.16 Both miR-1 and miR-206 promote myogenic differentiation,
while miR-133a and miR-133b maintain the undifferentiated state
and promote cell growth.17 Moreover, in some muscle disorders, such
as Duchenne muscular dystrophy and myotonic dystrophy type 1, it
has been reported that increases of miR-206, miR-1, miR-133a, and
miR-133b, may be useful biomarkers for monitoring muscle atrophy
and evaluating treatment outcomes.11,18
Muscle imaging is another emerging diagnostic tool for detecting
affected muscles through the identification of early fatty replacement
and the presence of intramuscular edema. It may be useful for follow-
ing disease progression.
In this study, we evaluated the levels of myomiRs and miRNAs
involved in lipid metabolism in an Italian family, in which three mem-
bers were affected. Moreover, we correlated miRNAs expression pro-
file with muscle imaging results.
2 | METHODS
We enrolled four members of one NLSDM family (patient 1, the
oldest brother [P1]; patient 2, the sister [P2]; patient 3, the younger
brother [P3]; the daughter of P1, heterozygous carrier) and 7 healthy
subjects (5 males and 2 females) matched for sex and age to patients.
The clinical data were collected during several outpatient
examinations.
Muscle qualitative evaluation was performed by computed
tomography (CT) scan and magnetic resonance imaging (MRI). In P3,
images of lower limb and right upper extremity muscles were acquired
using T1-weighted sequences by MRI. In P1, due to previous surgery,
we could only perform CT scanning. Muscle pattern was ranked
according to the Mercuri scale.19 All procedures were approved by
the local Institutional Review Board and conducted in accordance
with the ethical principles outlined in the Declaration of Helsinki. All
patients signed a written, informed consent.
Histopathological evaluation of quadriceps muscles of P1 and P3
was previously performed for diagnostic reason.
The miRNAs were isolated from 400 μL of serum using the
miRNeasy Mini Kit (QIAzol). A total of 10 ng of RNA were used to
determine individual miRNA level by real-time polymerase chain reac-
tion (qRT-PCR), performed using the CFX96™ Real-Time PCR detec-
tion System (Bio-Rad), with specific TaqMan MicroRNA Assay. The
expression level of each miRNA was normalized to miR-16, U6 snRNA,
and miR-39-3p of Caenorhabditis elegans, the first two as internal con-
trols and the other as spike-in miRNA, respectively. Primers sequences
are in Supporting Information Table S1, which is available online. Data
were obtained from at least three qRT-PCR experiments and each
sample was analyzed in duplicate. Relative expression was calculated
using the comparative ΔΔCt method. The Wilcoxon-Mann–Whitney
test for paired data for small samples was used to asses significance.
The level of statistical significance was set at P ≤ .05.
3 | RESULTS
We studied three affected family members, carrying two heterozy-
gous compound PNPLA2 mutations.6 These subjects exhibited highly
variable clinical features. Two male siblings, aged 61 and 50 years, had
F IGURE 2 Dysregulation of circulating selectedmiRNAs in a
NLSDM family in comparison to a control group. The bar graph represents
the relative expression of serummyomiRs (A) andmiRNAs involved in
lipid metabolism (B) in NLSDMpatients, comparedwith healthy subjects.
Data are presented asmean + SD, with control value set to 1. *P ≤ .05
(*). C, pool of controls; H, heterozygous carrier; P1, daughter; P1, NLSDM
male patient; P2, NLSDM female patient; P3, NLSDMmale patient [Color
figure can be viewed at wileyonlinelibrary.com]
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an asymmetric distal myopathy, while the 58-year-old sister showed
hepatosteatosis and type 2 diabetes as the main findings. Clinical and
laboratory findings are summarized in Table 1. CT scan (P1) and MRI
(P3) revealed fibro-fatty replacement in the lower and right upper
extremities (Figure 1A-E); lipid droplets were observed in muscle
biopsy of both patients (Figure 1F-I).
Expression level analysis revealed that patients exhibited a signifi-
cant elevation of serum myomiRs (Figure 2A). In particular, miR-206
was 28- to 38-fold higher than in control subjects, while miR-133a
was 4.7- to 9-fold higher. Also, miR-1 was increased in P1 and P2 up
to 10-fold, and miR-133b approximately 2-fold.
The investigation of some circulating miRNAs, mainly involved in
lipid metabolism, showed a significant up-regulation of miR-122, miR-
34a, and miR-155 (P < .05) in NLSDM patients, compared with control
group (Figure 2B). The expression profile of miR-378 and miR-27a
was significantly elevated only in P2 (Figure 2B).
4 | DISCUSSION
In our NLSDM brothers, CT scan/muscle MRI demonstrated that mus-
cle mass correlated with miR-206 levels. P1 presented walking diffi-
culties and advanced myopathy, whereas P3 had a slowly evolving
myopathy. Because miR-206 expression was lower in P1 than in P3, it
could be hypothesized that severe muscle damage partially or totally
prevents muscle regeneration.
In P2, whowasminimally symptomatic, hepatosteatosis was detected
by ECHO and a significant overexpression of miR-1 and miR-206 was
found. This can be explained by the observation that miR-1 and miR-206
are involved in lipid accumulation in hepatocytes.20
The miRNAs can also play an important role in the regulation of
lipid metabolism. The first identified was miR-122. Its suppression
causes a reduction of circulating cholesterol and TAG levels as well as
of hepatosteatosis.21 miR-34a regulates Sirtuin 1 (SIRT1) expression
and, consequently, plays important role in lipid metabolism.22 In path-
ological conditions, such as nonalcoholic fatty liver disease and obe-
sity, the overexpression of miR-34a causes SIRT1 inhibition, inducing
hepatic inflammation, a decrease of lipid metabolism gene expression
and increase of de novo lipogenesis.13,23 In our patients, we found a
positive correlation between the increase of miR-122 and miR-34a
and high levels of hepatic enzymes. In particular, we observed an
increase of these miRNAs in P2, who had hepatosteatosis, diabetes,
and abdominal fat accumulation.
It has been reported that miR-378 induces the expression of adi-
pocyte genes and lipid storage during adipogenesis,24 while miR-27a
negatively regulates the expression of some lipid metabolic genes.20
Consistent with this, these miRNAs showed a significant increase only
in P2. Recently, some studies showed that miR-378 is also expressed
in skeletal muscle and an increase of its plasma level was reported in
animal models of muscular dystrophy,25,26 and acute muscle injury.27
These data are not in agreement with the miR-378 profile observed in
NLSDM patients, as this miRNA was not significantly upregulated in
those patients showing substantial muscle involvement (P1, P3).
Further studies are needed to clarify whether miR-378 and miR-27a
play a role in human muscle metabolic disorders.28
Finally, our results also showed an increase of miR-155 in NLSDM
patients in comparison to the control group. MiR-155 has important
functions in inflammation and, recently, was described to contribute
to liver pathology and arteriosclerosis.29,30
In conclusion, we show that the increased expression levels of
muscle and lipid metabolism-specific miRNAs may be an indicator
of clinical phenotype. Because of the tissue-specific distribution of
numerous miRNAs, they are excellent biomarkers of muscle, heart, or
liver injuries. In NLSDM, multiple organs are affected; therefore, this
disease could have a very special serum miRNA signature providing a
powerful new tool. This could be further studied with more complete
profiling.
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